BMY · BRISTOL MYERS SQUIBB CO

531 filings

BMY SEC Filings

BRISTOL MYERS SQUIBB CO - 531 total filings

Filing record · 2016–202610-K1110-Q328-K169

Showing 1–50 of 531 filings

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Jul 30, 2026)

Bristol Myers Squibb reported second-quarter 2026 results that beat the company's trajectory and raised full-year guidance. Total revenues rose 6% (5% ex-FX) to $13.0 billion, led by the Growth Portfolio, which grew 15% (14% ex-FX) to $7.6 billion on strength in Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag. The Legacy Portfolio declined 4% to $5.4 billion, with Eliquis demand growth (up 22%) offsetting generic erosion from Revlimid, Pomalyst and others. Eliquis is now a key bright spot, with management guiding to 20%-25% worldwide growth for 2026. Profitability was mixed. GAAP EPS was $1.62 versus $0.64 a year ago, helped by the absence of last year's $1.5 billion acquired IPR&D charge and lower acquired-intangible amortization. Non-GAAP EPS was $2.04, up 40%. Gross margin slipped about 120 basis points on both bases due to product mix, and R&D rose 15% on a GAAP basis, driven by a priority review voucher purchase and higher IPR&D impairments. Net debt narrowed to about $31.7 billion from $34.0 billion at year-end 2025. Management raised 2026 guidance: revenue to roughly $49.0-$50.0 billion (from $46.0-$47.5 billion), non-GAAP diluted EPS to $6.75-$7.00 (from $6.05-$6.35), and operating expenses to about $16.5 billion. Gross margin, other expense and tax rate guidance were unchanged. Investors should note that guidance excludes future acquired IPR&D charges and licensing income, and that the 8-K's own forward-looking statements flag pricing pressure, generic competition and pipeline risk.

Jul 30, 2026 10-Q

BRISTOL MYERS SQUIBB CO Quarterly Report for Q2 Ended Jun 30, 2026

Bristol-Myers Squibb reported a strong second quarter of 2026, with total revenues of $12.97 billion, up 6% year over year, and GAAP diluted EPS of $1.62 versus $0.64 a year ago. The comparison is distorted by the prior-year $1.5 billion BioNTech upfront Acquired IPRD charge and $336 million of Mirati CVR fair value losses, so the more meaningful comparison is non-GAAP diluted EPS of $2.04, up 40% from $1.46. Growth was driven by the Growth Portfolio (up 15% in Q2, to $7.56 billion), led by Camzyos (+60%), Breyanzi (+41%), Reblozyl (+29%), and Cobenfy (+81%), along with Eliquis (+22%, aided by a U.S. list price cut that raised net realized prices). Legacy erosion remained steep, with Revlimid (-49%) and Pomalyst (-71%) down sharply on generic competition. Gross-to-net adjustments fell to 30% of gross sales in Q2 from 46% a year earlier, lifting net product sales 6%, though this partly reflects lower Medicaid and Medicare rebate accruals and a Eliquis list price reduction. Profitability improved on lower intangible amortization, which fell $786 million year to date after Pomalyst's acquired right was fully amortized in Q4 2025. R&D rose 15% in Q2 to $2.96 billion, including $643 million of specified-item IPRD impairments and a $220 million priority review voucher purchase. Cash generation was weaker: operating cash flow fell to $4.5 billion year to date from $5.9 billion, as lower net customer receipts (partly reflecting the Eliquis price cut) and a $3.1 billion rebates and discounts outflow weighed. Net debt improved modestly to $31.7 billion from $34.0 billion, helped by $1.7 billion of debt repayment, though cash and marketable securities declined to $11.5 billion from $11.1 billion, and dividends of $2.6 billion were paid for the half. The filing also highlights pipeline catalysts, including iberdomide's PDUFA date of August 17, 2026, Camzyos adolescent sNDA (PDUFA September 30, 2026), and mezigdomide (PDUFA May 13, 2027). Key risks include the IRA Medicare maximum fair price for Eliquis (effective 2026) and Pomalyst (2027), the Orencia selection for 2028 negotiation, EU apixaban composition-of-matter patent expiry in November 2026, the new Hengrui in-license deal, and a new Arkansas 340B lawsuit.

Jul 30, 2026 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Shareholder Vote Results (May 8, 2026)

Bristol Myers Squibb Company (BMY) held its Annual Meeting of Shareholders on May 5, 2026, as detailed in this 8-K filing. The meeting saw decisive votes on key corporate governance and executive matters. All 11 director nominees were overwhelmingly elected, indicating strong shareholder confidence in the current board's leadership and strategy. Furthermore, shareholders provided advisory approval for the compensation of named executive officers and ratified the company's 2026 stock award and incentive plan, signaling support for the company's incentive structures. Additionally, the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2026 received overwhelming ratification. However, a shareholder proposal advocating for an independent board chairperson was not approved, suggesting that the current governance structure, where the roles may be combined or held by a non-independent director, remains favored by the majority of shareholders at this time. Overall, the results reflect robust shareholder support for BMY's management, operational plans, and existing governance framework.

May 8, 2026 10-Q

BRISTOL MYERS SQUIBB CO Quarterly Report for Q1 Ended Mar 31, 2026

Bristol-Myers Squibb's first quarter 2026 results show GAAP revenue growth of 3% to $11.5 billion, with the Growth Portfolio up 12% to $6.2 billion, led by Breyanzi (+56%), Camzyos (+97%), Reblozyl (+16%), and Eliquis (+16%). Growth was partly offset by steep generic erosion in the Legacy Portfolio, where Revlimid fell 63% and Pomalyst 22%. Excluding foreign exchange, revenue rose only about 1%. GAAP diluted EPS rose to $1.31 from $1.20, mainly because amortization of acquired intangibles fell sharply ($437 million versus $830 million) after Pomalyst's product right was fully amortized. Non-GAAP diluted EPS fell to $1.58 from $1.80, reflecting the loss of diabetes royalty income that ended December 31, 2025, and a $410 million IPRD impairment in R&D. Cash generation weakened. Operating cash flow fell to $1.1 billion from $1.95 billion, driven by lower net customer receipts from the Eliquis list price cut and higher litigation disbursements, while rebates and discounts were a $3.5 billion outflow in the quarter. Dividend payments of $1.3 billion, plus $500 million of floating rate note repayment, meant the net debt position improved only modestly, by $436 million to $33.6 billion. Total cash and marketable securities were $10.9 billion. Management said liquidity is sufficient for at least the next few years. The filing also highlights regulatory and litigation exposure. The U.S. Government Agreement brings tariff relief through January 2029 and an exemption from future U.S. pricing mandates, though it requires Eliquis to be provided free to Medicaid and deep direct-to-patient discounts. Eliquis faces U.S. patent litigation with Azurity and European generic challenges ahead of EU composition-of-matter expiry in November 2026. The IRS transfer pricing dispute for 2008–2012 remains unresolved, and the Celgene securities class action is set to receive final approval in May 2026. Pipeline progress was notable, including positive Phase III data for mezigdomide and Camzyos in adolescents, and an FDA PDUFA date of August 17, 2026 for iberdomide.

Apr 30, 2026 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Apr 30, 2026)

Bristol Myers Squibb reported first-quarter 2026 results on April 30, 2026. Total revenues rose 3% (+1% ex-FX) to $11.5 billion, driven by the Growth Portfolio, which grew 12% (+9% ex-FX) to $6.2 billion on Camzyos, Breyanzi and Reblozyl. The Legacy Portfolio fell 6% (8% ex-FX) to $5.3 billion, as Eliquis demand gains (+16%) were more than offset by generic erosion from Revlimid, Pomalyst and Sprycel. GAAP EPS was $1.31 (up 9%), while non-GAAP EPS fell 12% to $1.58, largely because royalty income on diabetes products expired at the end of 2025 and the non-GAAP effective tax rate rose to 18.3% from 15.1%. Non-GAAP gross margin compressed about 280 bps to 70.3%, reflecting product mix. GAAP results were helped by a $410 million IPRD impairment charge in R&D, which was excluded from non-GAAP figures. Management reaffirmed full-year 2026 guidance of $46.0–$47.5 billion in revenue and non-GAAP EPS of $6.05–$6.35, and said both are trending toward the upper end of the ranges. Eliquis worldwide revenue is still guided to grow 10–15% in 2026, and the Legacy Portfolio is expected to decline 12–16%. The quarter also included regulatory and data milestones: Sotyktu received FDA approval for psoriatic arthritis, Opdivo was approved for Hodgkin lymphoma, and the company reported positive Phase 3 data for mezigdomide and Camzyos in adolescents. Net debt was $33.6 billion at quarter-end, down from $34.0 billion at year-end 2025, and about $5 billion of share repurchase authorization remained. Investors will be watching the 2026 pipeline readouts and the delivery of the remaining $2 billion in cost savings by the end of 2027.

Apr 30, 2026 10-K

BRISTOL MYERS SQUIBB CO Annual Report, Year Ended Dec 31, 2025

Bristol Myers Squibb's 2025 results were essentially flat on the top line but substantially stronger on profitability. Total revenues were $48.2 billion, down roughly 0.2% from $48.3 billion in 2024. U.S. revenues fell 2% to $33.3 billion, while international revenues rose 5% to $13.8 billion, helped by a 2-point FX tailwind. Growth Portfolio sales rose 17% to $26.4 billion, led by Opdivo (+8%), Reblozyl (+31%), Breyanzi (+82%), Camzyos (+77%), and Eliquis (+8% to $14.4 billion). This offset a 15% decline in the Legacy Portfolio to $21.8 billion, driven by generic erosion for Revlimid (-49%), Sprycel (-62%), Abraxane (-58%), and Pomalyst (-23%). Management expects continued Legacy erosion in 2026, primarily from Revlimid and Pomalyst in the U.S. GAAP EPS was $3.46, compared with a loss of $4.41 in 2024, which included a $12.1 billion non-deductible Karuna charge. Non-GAAP EPS rose to $6.15 from $1.15. The improvement mainly reflects far lower Acquired IPRD charges ($3.7 billion vs. $13.4 billion), lower amortization of acquired intangibles ($3.3 billion vs. $8.9 billion), and cost savings from the strategic productivity initiative, which targets about $2.0 billion in savings by end-2027. Selling, general and administrative expense fell 14% and R&D fell 11%. Operating cash flow was $14.2 billion, dividends were $5.0 billion, and net debt declined $4.4 billion to $34.0 billion after $8.7 billion of debt was retired in tender offers and make-whole redemptions. The key investor watch items are the pace of Legacy erosion, U.S. pricing pressure (average net selling prices fell 4% in 2025 and GTN adjustments rose to 47% of gross sales), and pipeline readouts through 2026-2027, including milvexian (LIBREXIA-AF and STROKE), Cobenfy in Alzheimer's psychosis, and the Eliquis European patent litigation. The IRA's Medicare negotiated price for Eliquis takes effect January 1, 2026, and the company has a December 2025 U.S. government agreement that adds tariff relief through January 2029.

Feb 11, 2026 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Feb 5, 2026)

Bristol Myers Squibb reported fourth-quarter and full-year 2025 results on February 5, 2026. Q4 total revenue rose 1% to $12.5 billion (flat ex-FX), with the Growth Portfolio up 16% to $7.4 billion, offset by a 15% decline in the Legacy Portfolio to $5.1 billion as Revlimid and Pomalyst generic erosion continued. Full-year revenue was $48.2 billion, essentially flat reported and down 1% ex-FX, while the Growth Portfolio grew 17% to $26.4 billion, led by Breyanzi, Camzyos, Reblozyl, Opdivo, and the immuno-oncology franchise. Eliquis demand grew, but this was more than offset by Legacy erosion and higher U.S. government channel rebates. Profitability was distorted by Acquired IPRD charges and licensing income. GAAP EPS was $0.53 for Q4 and $3.46 for the year, versus non-GAAP EPS of $1.26 and $6.15, respectively. Both measures include a net $(0.60) per-share hit in Q4 and $(1.40) for the year from IPRD charges, primarily the Orbital Therapeutics acquisition. Non-GAAP operating expenses fell as the strategic productivity initiative took hold, and amortization of acquired intangibles dropped sharply as Revlimid amortization rolls off. Net debt improved to $34.0 billion from $38.5 billion, and management says it achieved its targeted ~$10 billion debt paydown ahead of schedule. For 2026, BMS guided to revenue of approximately $46.0 to $47.5 billion, implying a Legacy decline of roughly 12% to 16%, and non-GAAP EPS of $6.05 to $6.35. Worldwide Eliquis revenue is expected to grow 10% to 15%. The company also raised its quarterly dividend 1.6% to $0.63 per share, its 17th consecutive annual increase. Management emphasized that 2026 is data-heavy, with several pivotal readouts expected in the second half, including milvexian AF and stroke trials, Cobenfy Alzheimer's psychosis trials, and mezigdomide and iberdomide in multiple myeloma.

Feb 5, 2026 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Regulation FD Disclosure (Jan 12, 2026)

Bristol Myers Squibb (BMY) furnished an investor presentation under Item 7.01 (Regulation FD) on January 12, 2026, timed to the 44th Annual J.P. Morgan Healthcare Conference, where CEO Christopher Boerner presented under the theme "Built for Growth." The filing contains no new financial results, guidance changes, or material transactions; it is a strategic update. The central message is management's goal of building a financially strong company with industry-leading sustainable growth into the 2030s, supported by a 2025 record of 17% growth in its Growth Portfolio (nine months ended 9/30/25 vs. prior year), four Growth Portfolio assets each annualizing over $1 billion based on Q3 2025 revenue, and completed business development deals. The presentation's main investor catalysts are its pipeline timeline. Management expects a dense slate of registrational readouts in 2026, including milvexian in atrial fibrillation (LIBREXIA-AF) and secondary stroke prevention, admilparant in IPF, iberdomide progression-free survival in RRMM, mezigdomide in RRMM, arlo-cel in 4L+ multiple myeloma, and RYZ101 in GEP-NETs. Management also highlighted a target of roughly 10+ new product launch opportunities by 2030, and capital allocation priorities of reinvesting in the business (R&D, AI) and returning capital, citing about $14.5B in dividends and about $8B in share repurchases over the past three years, plus 94 consecutive years of dividend payments. Investors should treat the presentation as forward-looking management commentary rather than audited results. It carries standard safe-harbor language flagging risks including drug pricing and most-favored-nation policy, patent exclusivity, clinical and regulatory timing, and legal proceedings. Pipeline timelines and multi-billion-dollar potential estimates are subject to trial outcomes and regulatory approval, so the key forward test is whether the 2026 readouts deliver on schedule.

Jan 12, 2026 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Nov 18, 2025)

On November 17–18, 2025, Bristol Myers Squibb (BMY) disclosed the results of its cash tender offers for its outstanding notes. As of the November 17, 2025 Early Tender Deadline, holders tendered substantial principal across both pools. The company reduced the Pool 1 maximum from $4.0 billion to about $3.99 billion, which was sufficient to accept all Pool 1 notes tendered early, and raised the Pool 2 maximum from $3.0 billion to about $3.51 billion. Under the amended terms, all tendered Pool 1 notes and all Pool 2 notes at acceptance priority levels 1 through 4 were accepted with no proration, while the 5.900% Notes due 2033 were accepted at a 50.84% proration factor, capped at $250 million. Notes at priority levels 6 through 9 were not accepted. The tender offers are a liability-management action in which BMY retires higher-coupon and near-term debt using cash. Early settlement is scheduled for November 20, 2025, and the offers expire December 3, 2025, but the company expects no final settlement because the early tender caps were met. The filing does not disclose the funding source for the purchases or the net effect on debt levels and interest expense. Those details would be in the Offer to Purchase or subsequent filings. For investors, the transaction is a debt management event rather than an operating or earnings event. It shows strong bondholder participation at the offered pricing, which suggests the company could retire a meaningful amount of debt. Total consideration per $1,000 principal ranged from about $985.66 to $1,129.13, and the offer yields ranged from roughly 3.7% to 6.1%, reflecting the spread between older coupons and current market rates.

Nov 18, 2025 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Nov 10, 2025)

Bristol Myers Squibb Company (BMY) has announced the successful completion of a significant public offering of €5.00 billion in aggregate principal amount of senior unsecured notes, issued by its wholly-owned Irish subsidiary, BMS Ireland Capital Funding Designated Activity Company. The offering comprises notes with maturities ranging from 2030 to 2055 and interest rates from 2.973% to 4.581%. These notes are fully and unconditionally guaranteed by Bristol Myers Squibb Company. The primary purpose of this capital raise is to fund the company's tender offer to repurchase various series of its outstanding notes, as well as to cover associated fees and expenses. Any remaining proceeds will be allocated for general corporate purposes. This debt issuance signifies a strategic move by Bristol Myers Squibb to manage its existing debt obligations and optimize its capital structure.

Nov 10, 2025 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Nov 3, 2025)

On November 3, 2025, Bristol-Myers Squibb (BMY) announced cash tender offers to repurchase up to $7 billion of its outstanding notes, split into two pools: Pool 1 (up to $4.0 billion across six series maturing 2026 through 2029) and Pool 2 (up to $3.0 billion across nine longer-dated series, including 2031 through 2097 maturities). The offers are funded by a concurrent new notes offering by its wholly-owned Irish finance subsidiary, BMS Ireland Capital Funding DAC, combined with roughly $3.0 billion of cash on hand. The offers are subject to a financing condition tied to that new issuance, and the company is not obligated to purchase any minimum amount of notes. The transaction is essentially a liability management exercise: BMY is retiring existing higher-coupon debt (many coupons of 5.1% to 6.9%) and refinancing it with new debt, while also reducing principal outstanding and potentially smoothing its maturity profile. Holders who tender by the early deadline of November 17, 2025 receive a $50 per $1,000 early tender premium plus a fixed spread over a Treasury reference yield, priced as of November 18, 2025. Later tenders receive a lower price that excludes the premium. Acceptance is governed by priority levels, with proration applied to the lowest-priority series if the pool caps are exceeded. For investors, the filing signals active balance sheet management rather than a change in operating performance. The filing does not disclose the size or pricing of the new notes, the amount of debt actually tendered, or the resulting interest expense savings, so those effects remain to be quantified in subsequent press releases. The company also reserves the right to redeem the 2026, 2027, and 2028 notes that remain outstanding after the offers, which could be a further step in reducing its debt stack.

Nov 3, 2025 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Oct 30, 2025)

Bristol Myers Squibb reported third-quarter 2025 results on October 30, 2025, with total revenues up 3% (2% ex-FX) to $12.2 billion. The quarter was driven by the Growth Portfolio, which rose 18% (17% ex-FX) to $6.9 billion on strength in immuno-oncology (Opdivo, Opdualag, Yervoy), Reblozyl, Breyanzi and Camzyos. The Legacy Portfolio fell 12% to $5.4 billion as generic erosion from Revlimid, Pomalyst and Sprycel more than offset strong Eliquis demand (+25%). U.S. revenue rose 1% to $8.3 billion and international revenue rose 6% (3% ex-FX). Profitability was mixed. GAAP EPS rose to $1.08 from $0.60, helped by much lower acquired intangible amortization ($831 million versus $2.4 billion a year earlier), but non-GAAP EPS fell 9% to $1.63 from $1.80. Both figures absorb a $(0.20) per-share net charge from Acquired IPRD and licensing activity, including the Philochem deal and a SystImmune milestone. Gross margin compressed to 71.9% GAAP and 72.9% non-GAAP, reflecting product mix, while SG&A fell 10% on the strategic productivity initiative. Management raised full-year 2025 revenue guidance to approximately $47.5 to $48.0 billion from $46.5 to $47.5 billion, citing Growth Portfolio strength. Non-GAAP EPS guidance was narrowed to $6.40 to $6.60 from $6.35 to $6.65, and now includes an $(0.80) per-share Acquired IPRD impact, up from $(0.60). The company also announced a definitive agreement to acquire Orbital Therapeutics, which is expected to close in Q4 2025, and reported net debt of $32.1 billion at quarter end, down from $38.5 billion at year end 2024.

Oct 30, 2025 10-Q

BRISTOL MYERS SQUIBB CO Quarterly Report for Q3 Ended Sep 30, 2025

Bristol-Myers Squibb's Q3 2025 10-Q shows a quarter with GAAP net earnings attributable to BMS of $2.2 billion ($1.08 diluted EPS) versus $1.2 billion ($0.60) a year ago, while total revenues rose 3% to $12.2 billion. Growth was driven by the Growth Portfolio, up 18% to $6.9 billion, with strong contributions from Opdivo, Reblozyl, Camzyos, Breyanzi and Eliquis (U.S. +29%). Offsetting this, the Legacy Portfolio fell 12% as generics eroded Revlimid (-59%), Pomalyst (-25%), Sprycel and Abraxane. Year-to-date revenues declined 1% to $35.7 billion, with U.S. revenues down 3% amid lower average net selling prices and the Medicare Part D redesign, which also pushed up GTN adjustments to 47% of gross sales in the quarter. The headline GAAP earnings improvement is largely a function of lower non-cash amortization of acquired intangibles (down to $831 million from $2.4 billion) and lower one-time Acquired IPRD charges year-to-date ($2.3 billion versus $13.3 billion in 2024, which included Karuna). Non-GAAP EPS, which excludes these items, was $1.63 in the quarter, down from $1.80, reflecting higher IPRD charges in Q3 2025 tied to the BioNTech, Philochem and SystImmune deals. Cost discipline is clearly visible: SG&A fell 19% year-to-date and R&D fell 8%, supported by the ongoing strategic productivity initiative, which management expects to deliver about $2.0 billion in annual savings by the end of 2027. Balance sheet and cash generation remained solid. Operating cash flow was $12.2 billion year-to-date, funding $3.8 billion of dividends and $2.2 billion of business development payments, while net debt improved by $6.4 billion to $32.1 billion. Cash and equivalents rose to $15.7 billion. Key risks flagged include U.S. drug-pricing policy (IRA negotiation, the most-favored-nation executive order), generic entry for Pomalyst in the U.S. in March 2026, Eliquis European generic erosion, and several material litigation matters, including the Celgene securities class action now subject to a settlement in principle.

Oct 30, 2025 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Jul 31, 2025)

Bristol Myers Squibb reported Q2 2025 total revenues of $12.3 billion, up 1% reported and flat on an ex-FX basis. The headline story is the mix shift: Growth Portfolio revenue rose 18% (17% ex-FX) to $6.6 billion, driven by immuno-oncology (Opdivo, Yervoy, Opdualag), Breyanzi, Reblozyl, Camzyos and early Cobenfy sales, while the Legacy Portfolio fell 14% to $5.7 billion as Revlimid, Pomalyst and Sprycel erosion from generics continued. U.S. revenue declined 3% and international grew 10%. Eliquis demand was up, though its U.S. growth was partly offset by Medicare Part D redesign effects. Profitability was dominated by a one-time $1.5 billion Acquired IPRD charge tied to the June 2025 BioNTech partnership for the BNT327 bispecific antibody, which reduced EPS by $0.57. GAAP diluted EPS was $0.64 (versus $0.83 a year earlier) and non-GAAP EPS was $1.46 (versus $2.07). Excluding the charge, underlying trends were supported by lower SG&A from the productivity initiative and a sharply lower amortization charge, which fell to $830 million from $2.4 billion as Revlimid intangibles amortized down. Gross margin compressed on product mix, to 72.5% GAAP and 72.6% non-GAAP. Management raised full-year 2025 total revenue guidance to about $46.5–$47.5 billion from $45.8–$46.8 billion, citing Growth Portfolio strength, better Legacy sales, and roughly $200 million of FX benefit. Non-GAAP EPS guidance was lowered to $6.35–$6.65 from $6.70–$7.00, reflecting the $0.57 BioNTech charge and roughly $300 million of higher operating expenses from business development and growth investments. Net debt declined to $35.2 billion from $38.5 billion at year-end 2024, and the company is on track to repay about $10 billion of debt by Q2 2026, with about $6.5 billion achieved.

Jul 31, 2025 10-Q

BRISTOL MYERS SQUIBB CO Quarterly Report for Q2 Ended Jun 30, 2025

Bristol-Myers Squibb's Q2 2025 results show a sharp contrast between GAAP and underlying performance. Total revenues rose 1% to $12.27 billion in the quarter, driven by Growth Portfolio demand (up 18%, led by Breyanzi, Opdivo, Reblozyl, Camzyos and Yervoy) and Eliquis (up 8%), which offset steep generic erosion in the Legacy Portfolio (down 14%, with Revlimid down 38%). Year-to-date revenues fell 2% to $23.47 billion. GAAP diluted EPS was $0.64, down from $0.83, primarily due to a $1.5 billion upfront payment to BioNTech recorded as Acquired IPRD. Non-GAAP diluted EPS was $1.46, down from $2.07. Year-to-date GAAP EPS of $1.85 compares favorably with a prior-year loss of $(5.05), which reflected the Karuna acquisition charge, but the comparison is distorted by one-time items in both periods. Margins and cash generation were supported by cost discipline. SG&A fell 11% in the quarter and 23% year-to-date, and R&D fell 11% and 14%, reflecting the strategic productivity initiative, which management now expects to deliver about $2.0 billion in annual savings by end-2027. Operating cash flow was $5.9 billion year-to-date, up from $5.2 billion, and cash plus marketable securities rose to $13.95 billion. Net debt declined $3.2 billion to $35.2 billion, and the company paid $2.5 billion in dividends. Pressures remain significant: U.S. net selling prices fell 7% year-to-date, the Medicare Part D redesign weighed on net pricing, a $700 million Hawaii Plavix settlement ($350 million paid by BMS) was recorded, and a $336 million non-cash contingent consideration charge reflected higher probability assumptions on the Mirati CVR. Looking ahead, the pipeline and business development activity is substantial. The BioNTech collaboration includes $2.0 billion in anniversary payments through 2028 and up to $7.6 billion in milestones, and the Philochem license adds a $350 million upfront payment expected in Q3 2025. Several late-stage readouts were mixed: Camzyos in nHCM and Cobenfy adjunctive schizophrenia did not meet their primary endpoints, and Reblozyl in myelofibrosis-associated anemia also missed. Pending catalysts include the Sotyktu PsA filings (PDUFA March 2026) and the Eliquis Medicare maximum fair price effective 2026. Investors will need to weigh the durability of Growth Portfolio momentum against accelerating Legacy erosion and IRA/MFN pricing exposure.

Jul 31, 2025 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Jul 25, 2025)

Bristol Myers Squibb (BMY) disclosed in an 8-K filed July 25, 2025 that Samit Hirawat, its Executive Vice President, Chief Medical Officer and Head of Development, will step down from that role effective August 1, 2025 and will remain an advisor to the company until his departure on November 1, 2025. He is leaving to pursue new professional opportunities. The company simultaneously announced the appointment of Cristian Massacesi, M.D., as EVP, Chief Medical Officer and Head of Development, effective August 1, 2025. Massacesi previously served as Chief Medical Officer of AstraZeneca and Alexion and as Oncology Chief Development Officer at AstraZeneca, and he will oversee early- and late-stage product development across all therapeutic areas, reporting directly to CEO Christopher Boerner. For investors, the filing signals a leadership transition in R&D, a function central to BMS's pipeline and long-term growth. The handoff appears planned, with an overlap period and an advisory role for Hirawat through November 1, 2025, and the incoming executive has a long track record in global clinical development and regulatory approvals. Financially, the filing discloses no material charges beyond standard severance, pro-rated equity vesting, and a pro-rated 2025 annual incentive payout under company plans, and the amounts are not quantified in the filing. The key items to monitor are whether Massacesi's arrival changes the pipeline priorities or timelines BMS has communicated, and whether any further senior R&D departures follow. Because the filing does not quantify the severance or equity acceleration, investors seeking the cost impact would need to look to later proxy or compensation disclosures.

Jul 25, 2025 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Shareholder Vote Results (May 7, 2025)

Bristol Myers Squibb Co. (BMY) held its Annual Meeting of Shareholders on May 6, 2025, as detailed in this 8-K filing. The meeting's primary outcomes revolved around shareholder votes on key corporate governance and executive matters. Notably, all 11 director nominees were overwhelmingly elected, indicating strong shareholder confidence in the current board's leadership and oversight. The company also received shareholder approval for the compensation of its named executive officers through an advisory vote, suggesting alignment between executive pay and shareholder interests. Furthermore, shareholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2025. In contrast, two shareholder proposals, one concerning Corporate Financial Sustainability and another requesting the cessation of DEI (Diversity, Equity, and Inclusion) Efforts, did not receive sufficient support to pass. These results reflect shareholder sentiment on strategic priorities and corporate social responsibility initiatives.

May 7, 2025 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Apr 24, 2025)

Bristol Myers Squibb reported first-quarter 2025 results on April 24, 2025, with total revenues of $11.2 billion, down 6% year over year (down 4% excluding foreign exchange). The headline decline reflects the steep erosion of the Legacy Portfolio, which fell 20% to $5.6 billion, driven by generic competition to Revlimid, Pomalyst, Sprycel and Abraxane and the Medicare Part D redesign. The Growth Portfolio grew 16% (18% ex-FX) to $5.6 billion, led by Opdivo, Breyanzi, Reblozyl and Camzyos, with an early U.S. launch of Cobenfy also contributing. The Growth Portfolio now roughly equals the Legacy Portfolio in quarterly sales, which is the central transition the company is managing. Profitability improved sharply versus the prior-year quarter, which included a $12.9 billion Acquired IPRD charge tied to the Karuna acquisition. GAAP EPS was $1.20 and non-GAAP EPS was $1.80, compared with a GAAP loss of $5.89 and a non-GAAP loss of $4.40 a year earlier. Gross margin compressed modestly on product mix, while SG&A and R&D fell on the strategic productivity initiative. Management raised full-year 2025 non-GAAP EPS guidance to $6.70 to $7.00 and revenue guidance to approximately $45.8 to $46.8 billion, citing about $500 million of favorable FX and better-than-expected Legacy sales. Investors should note that the guidance raise is largely FX-driven, and that setbacks in the quarter included the Phase 3 ARISE trial of Cobenfy and the ODYSSEY-HCM trial of Camzyos, both of which missed their primary endpoints. Balance sheet progress was also noted, with net debt improving to $37.6 billion from $38.5 billion at year-end 2024 and management targeting about $10 billion of debt reduction by the end of the first half of 2026, of which roughly $6 billion had been achieved as of Q1 2025. The company is still exposed to tariff risk, since the guidance excludes potential pharmaceutical sector tariffs.

Apr 24, 2025 10-Q

BRISTOL MYERS SQUIBB CO Quarterly Report for Q1 Ended Mar 31, 2025

Bristol-Myers Squibb's first-quarter 2025 results show a mixed picture. Total revenues fell 6% year over year to $11.2 billion, as generic erosion on Revlimid, Pomalyst, Sprycel and Abraxane, plus the Medicare Part D redesign affecting Eliquis pricing, offset strong demand growth in the Growth Portfolio (up 16% to $5.6 billion). U.S. net selling prices declined 8%, and U.S. gross-to-net adjustments rose to 51% of gross sales from 45%. Reported GAAP diluted EPS was $1.20, versus a loss of $(5.89) in Q1 2024 that was driven by the $12.1 billion Karuna acquired IPRD charge. Non-GAAP diluted EPS was $1.80, versus $(4.40) a year earlier, and the comparison is distorted by the 2024 one-time charges and acquisition-related items. Cash generation weakened. Operating cash flow was $1.95 billion, down from $2.83 billion, mainly because of higher U.S. GTN payments. Net debt improved by $886 million to $37.6 billion, aided by $12.1 billion of cash and marketable securities. Dividends of $1.26 billion were paid, and the company retains $5.0 billion of remaining buyback capacity. Total debt is $49.5 billion, and short-term obligations rose to $3.6 billion as the current portion of long-term debt increased. Operating cost discipline is improving. SG&A fell 33% and R&D fell 16%, largely because 2024 included acquisition-related stock settlements. Management expects about $2.0 billion of annual cost savings by the end of 2027 from its expanded productivity program, with the 2023 Restructuring Plan's total charges now estimated at about $2.5 billion. Pipeline and regulatory news was mixed. Breyanzi, Camzyos, Opdivo and Opdivo plus Yervoy won several approvals, including a U.S. approval for first-line HCC and CRC. However, the Phase III ODYSSEY-HCM (Camzyos in nHCM) and ARISE (Cobenfy adjunctive) trials missed their primary endpoints, and RELATIVITY-098 (Opdualag adjuvant) also failed.

Apr 24, 2025 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Feb 18, 2025)

Bristol Myers Squibb Company (BMY) has filed an 8-K report announcing the upcoming retirement of Sandra Leung, Executive Vice President and General Counsel. Ms. Leung intends to retire in 2025 and will remain with the company for a transition period to ensure a smooth handover of her responsibilities. This change in a key executive role warrants investor attention as leadership transitions can sometimes impact strategic direction and operational continuity. Ms. Leung is eligible for retirement benefits under the company's existing compensation plans. While the report does not detail the specific benefits, it confirms adherence to established policies. Investors should monitor future filings for announcements regarding Ms. Leung's successor, as the appointment of a new General Counsel is a significant development for the company's legal and governance framework.

Feb 18, 2025 10-K

BRISTOL MYERS SQUIBB CO Annual Report, Year Ended Dec 31, 2024

Bristol-Myers Squibb's FY2024 results were dominated by a one-time, non-tax-deductible Acquired IPRD charge tied to the Karuna acquisition ($12.1 billion, about $6.28 per share of GAAP EPS impact including the SystImmune upfront). As a result, the company reported a GAAP net loss attributable to BMS of $8.9 billion, or $(4.41) per diluted share, versus GAAP EPS of $3.86 in 2023. Excluding specified items, non-GAAP EPS fell to $1.15 from $7.51. Underlying top-line performance was healthier: total revenues rose 7% to $48.3 billion, driven by the Growth Portfolio (up 17% to $22.6 billion, led by Opdivo, Reblozyl, Breyanzi, Camzyos and Yervoy) and Eliquis (up 9%), partly offset by generic erosion in the Legacy Portfolio (Revlimid down 5%, Sprycel down 33%). Gross-to-net adjustments rose to 44% of gross product sales, a signal of continued pricing pressure. The balance sheet absorbed the acquisition spending. Net debt rose to $38.5 billion from $27.1 billion, long-term debt to $47.6 billion, and the company issued $13.0 billion of senior notes in 2024. Operating cash flow was $15.2 billion, but investing outflows of $21.4 billion reflected the Mirati, RayzeBio and Karuna payments. No share repurchases were made in 2024, with $5.0 billion of authorization remaining, and dividends of $2.42 per share were maintained. Management guided to roughly $1.5 billion of capex in 2025 and expanded its productivity program to about $2.0 billion of additional annual savings by 2027. The key investor debate is durability. Eliquis and Opdivo face loss of exclusivity around 2028, the IRA is set to bring Eliquis Medicare pricing in 2026 and Pomalyst negotiation in 2027, and BMS carries $23.3 billion of other intangible assets, with $2.9 billion of impairments recorded in 2024. Offsetting this, the pipeline now includes Cobenfy, the Krazati and RayzeBio assets, and multiple registrational readouts expected through 2025 and 2026.

Feb 12, 2025 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Feb 6, 2025)

Bristol Myers Squibb reported Q4 2024 revenues of $12.3 billion, up 8% (9% ex-FX), with the Growth Portfolio reaching $6.4 billion (+21%, or +23% ex-FX) and Legacy Portfolio revenues declining 4% to $6.0 billion. GAAP EPS was $0.04 versus $0.87 a year earlier, driven by intangible asset impairments and IPR&D charges, while non-GAAP EPS was $1.67 versus $1.70. For full year 2024, revenues were $48.3 billion (+7%, +9% ex-FX), but GAAP results showed a loss of $(4.41) per share, largely due to a one-time ~$12.1 billion acquired IPR&D charge tied to the Karuna acquisition and an ~$0.8 billion SystImmune collaboration charge. Non-GAAP EPS was $1.15, down from $7.51, reflecting roughly $(6.39) per share of net IPR&D impact. Management emphasized the ongoing shift toward the Growth Portfolio, highlighting strong demand for Reblozyl, Breyanzi, Camzyos and Opdualag, the U.S. launch of Cobenfy in schizophrenia, and the U.S. approval of Opdivo Qvantig. The company expanded its strategic productivity initiative to deliver about $2 billion in additional annualized cost savings by the end of 2027, with roughly $1 billion expected in 2025. Net debt rose to $38.5 billion from $27.1 billion at year-end 2023, and management plans to pay down about $10 billion of debt by the end of the first half of 2026. For 2025, guidance calls for total revenues of about $45.5 billion, reflecting an expected 18-20% decline in the Legacy Portfolio from generic erosion (notably Revlimid, Pomalyst, Sprycel and Abraxane) and roughly $500 million of FX headwind. Non-GAAP EPS is guided to $6.55-$6.85, with gross margin near 72% and operating expenses near $16 billion. Investors will focus on whether Growth Portfolio momentum and cost savings can offset the Legacy cliff, and on the sustainability of the Cobenfy launch and the pipeline readouts planned for 2025-2027.

Feb 6, 2025 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Regulation FD Disclosure (Jan 13, 2025)

Bristol Myers Squibb (BMY) furnished an investor presentation under Item 7.01 (Regulation FD) on January 13, 2025, timed to the 43rd annual J.P. Morgan Healthcare Conference. The 8-K itself contains no new financial results, guidance changes, or material transactions; its value lies in the strategic update delivered by CEO Christopher Boerner. The information is furnished, not filed, so it does not carry Section 18 liability, and the presentation's forward-looking statements and non-GAAP figures are caveated accordingly. The core message is a pivot to "sustained top-tier growth by the end of the decade," anchored by a Growth Portfolio that management expects to exceed 50% of revenues in 2025. Key drivers include Cobenfy (schizophrenia, launched late October 2024, with TRx tracking ahead of branded schizophrenia launch benchmarks and Medicare/Medicaid coverage ahead of expectations), Camzyos, Breyanzi, Reblozyl, and Opdivo Qvantig. Management also highlighted a dense 2025–2027 catalyst calendar, including Phase 3 readouts for Cobenfy (ARISE, ADEPT-2), Camzyos nHCM (ODYSSEY), Reblozyl (INDEPENDENCE), and Opdualag adjuvant melanoma, plus the milvexian program across three indications. For investors, the balance-sheet and capital-allocation commitments are central: a planned $10 billion debt paydown by 1H'26 (relative to March 31, 2024 debt levels), roughly $1.5 billion in annualized cost savings by end-2025, and a 93-year dividend record. Because the document is a promotional presentation rather than audited disclosure, the stated targets and timelines are management's expectations and remain subject to clinical, regulatory, and commercial risk.

Jan 13, 2025 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Oct 31, 2024)

Bristol Myers Squibb reported third quarter 2024 results on October 31, 2024, with total revenues of $11.9 billion, up 8% reported and 10% excluding foreign exchange. The Growth Portfolio was the main driver, with revenues of $5.8 billion, up 18% reported and 20% ex-FX, led by Reblozyl, Breyanzi, Camzyos, and Opdualag. The Legacy Portfolio grew 1% to $6.1 billion, supported by Eliquis (up 11%), which offset steep erosion in Sprycel (down 44%) following U.S. generic entry. The most notable regulatory event was the U.S. FDA approval of Cobenfy (xanomeline and trospium chloride) for schizophrenia on September 26, 2024, which management describes as the first new pharmacological mechanism for the condition in decades. Management expects the majority of patient access by the second half of 2025. Profitability was mixed. GAAP EPS fell 35% to $0.60 from $0.93, and non-GAAP EPS fell 10% to $1.80 from $2.00. Both figures include a net $(0.09) per share charge from acquired IPRD and licensing income. GAAP gross margin declined to 75.1% from 77.1%, and the GAAP effective tax rate rose to 27.5% from 9.5%. Interest expense rose to $505 million from $280 million, reflecting higher debt after recent acquisitions. Net debt stood at $41.3 billion at September 30, 2024, versus $27.1 billion at year-end 2023. Management reported that total debt was reduced by about $2.7 billion in the quarter and by about $5.9 billion over Q2 and Q3, and it targets roughly $10 billion of debt paydown by the end of 1H 2026. Full-year 2024 guidance was raised. Reported revenue growth is now expected at about 5% (about 6% ex-FX), and non-GAAP EPS guidance was raised to $0.75 to $0.95 from $0.60 to $0.90. Investors should note that the CheckMate-8HW trial met its primary endpoint, while CheckMate-901 missed its overall survival endpoint in urothelial carcinoma. The company also flagged increased Q4 operating expense investment and expected pressure on Abraxane U.S. sales from generic entrants.

Oct 31, 2024 10-Q

BRISTOL MYERS SQUIBB CO Quarterly Report for Q3 Ended Sep 30, 2024

Bristol-Myers Squibb's Q3 2024 10-Q shows a sharp swing to a nine-month GAAP net loss of $9.0 billion (EPS of -$4.45), driven almost entirely by a one-time $12.1 billion non-tax-deductible Acquired IPRD charge for the Karuna asset acquisition (Cobenfy) plus the $0.3B SystImmune upfront and other IPRD items. Excluding these and other specified items, non-GAAP diluted EPS for the nine months was -$0.53 versus $5.80 a year earlier, while the third quarter itself was stable: GAAP diluted EPS of $0.60 (vs. $0.93) and non-GAAP EPS of $1.80 (vs. $2.00). Underlying sales growth was solid, with total revenues up 8% in Q3 and 7% year-to-date to $35.96 billion, led by the Growth Portfolio (up 18% in Q3) and Eliquis, offset by generic erosion on Sprycel and Revlimid. The balance sheet has been materially reshaped by acquisitions. Cash used in investing activities rose to $21.2 billion, funded largely by a $13.0 billion senior unsecured notes issuance and cash on hand. Net debt rose by $14.2 billion to $41.3 billion, long-term debt reached $48.7 billion, and shareholders' equity fell to $17.1 billion from $29.4 billion at year-end 2023, mainly because of the net loss. Operating cash flow of $10.8 billion still covered the $3.6 billion dividend, though interest expense is climbing (about $1.5 billion year-to-date versus $0.85 billion a year earlier). Investors should weigh the strong launch trajectory of Cobenfy (FDA-approved in September 2024), Breyanzi, Camzyos, Opdivo and Reblozyl against the medium-term pressures: the IRA price-setting for Eliquis effective 2026, European and U.S. generic challenges to Eliquis and Zeposia, rising leverage, and a $1.5 billion annual cost-savings program targeted by end-2025. The company also disclosed that Keytruda royalty income is declining as the rate steps down to 2.5% in 2024.

Oct 31, 2024 10-Q

BRISTOL MYERS SQUIBB CO Quarterly Report for Q2 Ended Jun 30, 2024

Bristol-Myers Squibb's Q2 2024 10-Q shows a sharp GAAP swing driven by one-time acquisition accounting. Six-month total revenues rose 7% to $24.1 billion (U.S. +10%, International flat, FX-hit by ~5% from the Argentine peso), with the Growth Portfolio up 13% to $10.4 billion, led by Opdivo, Reblozyl, Camzyos, Breyanzi and Krazati, while Legacy Portfolio grew 2%, with Eliquis up 8% offsetting Revlimid's decline. However, year-to-date GAAP results turned to a net loss of $10.2 billion (diluted EPS of -$5.05, versus +$2.06 a year earlier), primarily due to $13.1 billion of Acquired IPRD charges, including $12.1 billion for the Karuna asset acquisition, which is not tax-deductible. Excluding specified items, non-GAAP diluted EPS was -$2.33 year-to-date versus $3.80 in 2023, and Q2 non-GAAP EPS was $2.07, up from $1.75. The balance sheet and cash flow picture has changed materially. Long-term debt rose to $48.9 billion (total debt about $52.4 billion including current portion), up from roughly $36.7 billion at year-end 2023, after BMS issued $13.0 billion of senior notes to fund the RayzeBio and Karuna acquisitions. Net debt climbed to $45.4 billion from $27.1 billion, and shareholders' equity fell to $17.0 billion from $29.4 billion, largely reflecting the large IPRD charge. Operating cash flow of $5.2 billion (up modestly year-over-year) continued to cover the $2.4 billion dividend, but the company's focus has shifted toward deleveraging, with the $1.5 billion annual productivity program and portfolio prioritization (including a $590 million alnuctamab IPRD impairment) as near-term levers. Key items for investors to monitor include the Eliquis European generic challenges and Medicare price negotiation starting in 2026, the Karuna KarXT FDA decision (PDUFA September 26, 2024), Revlimid and Abecma erosion, and the ongoing Plavix and Thalomid/Revlimid litigation. The company also recognized a $644 million tax reserve release related to Celgene's IRS audit, which benefited Q2 GAAP results.

Jul 26, 2024 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Jul 26, 2024)

Bristol Myers Squibb reported second-quarter 2024 results on July 26, 2024, with total revenues of $12.2 billion, up 9% reported (+11% excluding foreign exchange). The growth was led by the Growth Portfolio, which reached $5.6 billion, up 18% reported (+21% ex-FX), driven by Opdivo, Reblozyl, Camzyos and Opdualag, partially offset by Abecma. Legacy Portfolio revenues were $6.6 billion, up 2%, with Eliquis and Pomalyst growth offset by Revlimid generic erosion. U.S. revenues rose 13% to $8.8 billion, while International revenues fell 1% to $3.4 billion, reflecting a 7-point foreign exchange headwind. Profitability was mixed. GAAP EPS fell to $0.83 from $0.99, weighed by a $280 million intangible asset impairment, a $590 million IPRD impairment tied to discontinuing alnuctamab, higher interest expense from debt raised for acquisitions, and restructuring costs. Non-GAAP EPS rose to $2.07 from $1.75, aided by a $502 million income tax reserve release that lowered the non-GAAP effective tax rate to 14.1%. Investors should note that the GAAP tax benefit was $398 million on pre-tax earnings of $1.3 billion, so the reserve release materially flattered the quarter. Net debt rose to roughly $45.4 billion from $27.1 billion at year-end 2023. Management raised its 2024 non-GAAP guidance, with total revenue now expected at the upper end of the low single-digit growth range and diluted EPS raised to $0.60–$0.90 from $0.40–$0.70. Pipeline news included positive Phase 3 cendakimab data in eosinophilic esophagitis, FDA approvals for Breyanzi in follicular and mantle cell lymphoma, and a subcutaneous nivolumab BLA with a PDUFA date of December 29, 2024. The Phase 3 CheckMate-73L trial in stage III NSCLC missed its primary endpoint, and KarXT's FDA decision is set for September 26, 2024.

Jul 26, 2024 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Jun 18, 2024)

Bristol-Myers Squibb (BMY) filed a Form 8-K on June 18, 2024 to disclose the Board's election of Michael R. McMullen as a director, effective July 1, 2024. The Board size increases from ten to eleven in connection with the appointment. This is a governance event rather than a financial one: the filing contains no financial statements, earnings results, guidance, or material operational changes. Mr. McMullen, 63, is the former President and CEO of Agilent Technologies (2015-2024), where he is credited with nearly tripling market capitalization and driving margin and growth improvements. He is currently a senior advisor to Agilent's new CEO through October 31, 2024, and sits on the KLA Corporation board. The Board has determined he is independent under NYSE standards, and he will join the Audit Committee effective July 1, 2024. The filing states there are no related-party transactions and no arrangements under which he was selected. For investors, the appointment adds a director with large-scale operating and capital-markets experience and strengthens audit oversight. Compensation is standard for non-employee directors: a $110,000 annual cash retainer and $210,000 in deferred share units. The filing does not signal a change in strategy, but the Audit Committee addition and the stated focus on pipeline progress and capital allocation are worth monitoring.

Jun 18, 2024 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Bylaw Amendment (May 9, 2024)

Bristol-Myers Squibb Company (BMY) filed an 8-K report detailing the outcomes of its Annual Meeting of Shareholders held on May 7, 2024. The most significant event for investors is the shareholder approval of an amendment to the company's Certificate of Incorporation. This amendment, effective May 7, 2024, aims to eliminate or limit the monetary liability of specified executive officers for breaches of the duty of care. This change in governance structure could impact executive decision-making and the company's overall risk profile. In addition to the liability amendment, the report indicates that shareholders overwhelmingly re-elected all 10 director nominees, approved the compensation of named executive officers on an advisory basis, and ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2024. Conversely, two shareholder proposals—one advocating for an independent Board Chairperson and another for adopting a Board policy on executive retention of significant stock—did not receive majority approval.

May 9, 2024 10-Q

BRISTOL MYERS SQUIBB CO Quarterly Report for Q1 Ended Mar 31, 2024

Bristol-Myers Squibb's first-quarter 2024 results were dominated by a one-time, non-cash-to-EPS-neutral but cash-relevant acquisition charge. Total revenues rose 5% to $11.9 billion, led by Growth Portfolio products such as Reblozyl (+72%), Opdualag (+76%) and Camzyos, along with Eliquis (+9%). However, GAAP net loss attributable to BMS was $(11.9) billion, or $(5.89) per diluted share, versus $2.26 billion ($1.07) a year earlier. The swing reflects $12.9 billion of Acquired IPRD expense, principally the $12.1 billion Karuna asset acquisition (KarXT), plus the $800 million SystImmune upfront payment. Non-GAAP diluted EPS was $(4.40) versus $2.05 in the prior year, a $6.45 decline driven by the same IPRD charges and higher operating and interest expense from recent deals. The quarter marked a significant shift in the balance sheet. BMS spent roughly $20.1 billion on acquisitions, collaborations and milestones (Karuna, RayzeBio, Mirati, SystImmune), funded primarily through $13.0 billion of new senior unsecured notes and $3.0 billion of commercial paper. Total debt rose to about $52.4 billion, and the net debt position increased by $18.5 billion to $45.6 billion. Operating cash flow was still healthy at $2.8 billion, but it covered only a fraction of dividend and investment needs in the period, and the company is now explicitly prioritizing deleveraging. Management reaffirmed its investment-grade rating goal and its commitment to growing the dividend. Investors should weigh the headline loss against underlying franchise trends. Eliquis and the Growth Portfolio are offsetting erosion in Revlimid, Sprycel and Opdivo, with Abecma and Opdivo U.S. sales both declining. Key forward risks include Eliquis's IRA-driven government price negotiation beginning in 2026, European generic challenges to Eliquis, Revlimid generic erosion, and the pending litigation and tax matters disclosed in the filing. The strategic productivity program targeting about $1.5 billion in annual savings by end-2025 is a key lever for restoring margins.

Apr 25, 2024 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Apr 25, 2024)

Bristol Myers Squibb reported first-quarter 2024 revenues of $11.9 billion, up 5% reported (6% excluding foreign exchange), driven by Eliquis, Reblozyl, and Opdualag, partly offset by Opdivo and Revlimid. Growth Portfolio revenues rose 8% to $4.8 billion (11% ex-FX), while the Legacy Portfolio grew 2% to $7.1 billion. The top-line story was solid, but the bottom line was dominated by a one-time charge: GAAP loss per share was $(5.89) and non-GAAP loss per share was $(4.40), versus GAAP EPS of $1.07 and non-GAAP EPS of $2.05 a year earlier. The loss stems from $12.9 billion in Acquired IPRD charges, primarily the roughly $12.1 billion Karuna Therapeutics asset acquisition, plus the SystImmune collaboration. The Karuna charge is non-tax-deductible, which pushed the non-GAAP effective tax rate to about 9.0% negative for the quarter and drives the revised full-year tax rate assumption to roughly 69%. Management revised 2024 non-GAAP diluted EPS guidance to $0.40-$0.70 from $7.10-$7.40, reflecting a ~$6.73 impact from acquired IPRD charges and dilution from the Karuna and RayzeBio transactions. Revenue, gross margin, and operating expense guidance were left unchanged, and management stated there is no change to the underlying business outlook. Other income/(expense) guidance was revised to roughly ($250M) from roughly $250M to reflect acquisition financing costs. Net debt rose sharply to about $45.6 billion at March 31, 2024 from $27.1 billion at year-end 2023, and total debt is roughly $55.7 billion. Management plans to pay down about $10 billion of debt over two years and announced a strategic productivity initiative targeting roughly $1.5 billion in cost savings by the end of 2025, with most savings to be reinvested in growth. For investors, the key questions are whether the newly acquired pipeline, particularly KarXT (PDUFA September 26, 2024), Krazati, and Opdualag, can offset the Opdivo erosion and Revlimid decline, and how quickly leverage is reduced. The quarter also included several regulatory approvals, including Abecma in earlier-line multiple myeloma and Breyanzi in CLL/SLL, and a positive Phase 3 result for Opdivo plus Yervoy in hepatocellular carcinoma.

Apr 25, 2024 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Mar 18, 2024)

Bristol Myers Squibb Company (BMY) announced a change in its Board of Directors composition. Gerald Storch has informed the Board that he will not seek re-election at the upcoming 2024 Annual Meeting of Shareholders, scheduled for May 7, 2024. This decision means Mr. Storch will step down from his board position after this meeting. Following this departure, the Board has decided to reduce its size from its current number to ten directors, effective immediately after the 2024 Annual Meeting. Investors should monitor any further announcements regarding director nominations or changes in board committee memberships, as these can sometimes signal strategic shifts or governance considerations, though the primary impact here appears to be a routine board refreshment.

Mar 18, 2024 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Mar 18, 2024)

On March 18, 2024, Bristol-Myers Squibb (BMS) completed its acquisition of Karuna Therapeutics, and Karuna is now a wholly owned subsidiary. Each outstanding share of Karuna common stock (excluding certain excluded shares) was converted into the right to receive $330.00 in cash, without interest and subject to required withholding taxes. Karuna's shares have stopped trading on the Nasdaq Global Select Market. The main asset is KarXT (xanomeline-trospium), an antipsychotic with a novel mechanism of action for schizophrenia, which has a PDUFA date of September 26, 2024. It is also in registrational trials for adjunctive schizophrenia therapy and for psychosis in Alzheimer's disease, with potential expansion to bipolar I disorder and Alzheimer's disease agitation. BMS also gained Karuna's early-stage and preclinical pipeline. The financial impact is front-loaded and largely non-recurring. The transaction is accounted for as an asset acquisition, which produces an approximately $12 billion one-time, non-deductible Acquired In-Process Research and Development (IPR&D) charge. This charge reduces both GAAP and non-GAAP EPS by about $5.93 in the first quarter of 2024 and for full-year 2024. Separately, BMS expects the deal to dilute non-GAAP diluted EPS by about $0.30 in 2024, driven mainly by financing costs from a recently completed debt issuance. BMS plans to offset operating costs through resource allocation, cost efficiencies and portfolio prioritization, and says it will maintain its investment-grade credit ratings, continue business development, and keep paying dividends and repurchasing shares. Investors should read the transaction alongside BMS's February 2, 2024 outlook. BMS will update its financial outlook when it reports first-quarter 2024 results on April 25, 2024. The filing's forward-looking statements highlight risks, including whether KarXT's commercial potential and expected synergies are realized, possible legal proceedings related to the merger agreement, and employee retention.

Mar 18, 2024 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Feb 22, 2024)

On February 22, 2024, Bristol-Myers Squibb completed a $13.0 billion public offering of senior unsecured notes across nine tranches, comprising a $500 million floating rate note due 2026 and eight fixed rate series maturing between 2026 and 2064. The fixed rate coupons range from 4.900% to 5.650%, and the notes were issued under the 1993 base indenture with The Bank of New York Mellon as trustee, supplemented by a Fifteenth Supplemental Indenture. The notes carry customary covenants limiting secured debt, sale/leaseback transactions, and mergers, along with customary events of default. The company intends to use a portion of the proceeds to fund the cash consideration and related fees for its proposed acquisitions of Karuna Therapeutics and RayzeBio, with any remaining proceeds going to general corporate purposes. The offering is not contingent on those acquisitions. If the Karuna acquisition is not completed by the outside date (the later of June 30, 2025, or any extended End Date) or the company abandons it, a Special Mandatory Redemption would require repayment at 101% of principal for the floating rate notes and the 2026, 2027, 2029, and 2031 notes, totaling about $5.5 billion. The 2034, 2044, 2054, and 2064 notes (about $7.5 billion) would remain outstanding in that scenario. For investors, the filing shows a large, long-dated debt raise that locks in fixed financing costs for the acquisitions, with a notable tilt toward long maturities. The make-whole call provisions and the Special Mandatory Redemption feature are the key contingent terms to monitor. Because the filing predates the deal closings, the actual outcome of the acquisitions should be checked against later company disclosures.

Feb 22, 2024 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Feb 15, 2024)

Bristol Myers Squibb Company (BMY) announced a key leadership change within its finance department. Effective February 15, 2024, Phil Holzer has been appointed as the new Senior Vice President and Controller. Mr. Holzer brings extensive experience to this role, having been with the company since 2001 and most recently serving as Senior Vice President, Finance, Treasury and Tax Operations since 2021. This appointment signifies a transition as the current Senior Vice President and Controller, Ms. Sharon Greenlees, will be moving to another role within the company. Investors should view this as a normal course of business succession planning. Mr. Holzer's long tenure and diverse financial leadership positions within BMY suggest a stable internal promotion, which typically indicates continuity in financial strategy and operations. The filing also notes that Mr. Holzer is not involved in any reportable related-party transactions or arrangements related to his appointment.

Feb 15, 2024 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Feb 14, 2024)

On February 14, 2024, Bristol Myers Squibb (BMY) disclosed in an 8-K that it had become aware of an unsolicited "mini-tender" offer from Tutanota LLC to purchase up to 500,000 shares of BMY common stock at $55.00 per share. The shares sought represent less than 0.025% of BMY's outstanding common stock as of February 6, 2024, so the offer is financially immaterial to the company's capitalization, balance sheet, and operations. The filing does not report any financial results, guidance changes, or operational developments; it is a shareholder-protection communication. The company's press release, filed as Exhibit 99.1, recommends that stockholders not tender their shares. BMY highlights that the $55.00 offer price was below the prevailing market price at the time, meaning tendering stockholders would receive less than market value if the offer's conditions were satisfied. The offer is scheduled to expire at 5:00 p.m. ET on Friday, February 23, 2024, but Tutanota reportedly expects to extend it in successive 45- to 180-day periods, which could delay payment. BMY also notes the offer is subject to conditions, including Tutanota obtaining financing, and that the company has no affiliation with Tutanota. For investors, the key takeaway is that this is a low-risk, non-material event that requires no change in investment thesis. The main actionable point is that shareholders should not tender shares at the below-market price, should check current market quotes before responding to any mini-tender solicitations, and can withdraw any previously tendered shares before expiration. The filing also references SEC investor alerts on mini-tender offers as additional guidance.

Feb 14, 2024 10-K

BRISTOL MYERS SQUIBB CO Annual Report, Year Ended Dec 31, 2023

Bristol-Myers Squibb's FY2023 10-K shows a company in a transition year. Total revenues fell 2% to $45.0 billion, driven by Revlimid's generic erosion (down 39% to $6.1 billion) and free-goods distribution through the patient assistance foundation. Growth came from the New Product Portfolio (up 77% to $3.6 billion) and In-Line Products (Opdivo up 9%, Eliquis up 4%). GAAP diluted EPS rose to $3.86 from $2.95, mainly from specified items such as a $656 million non-U.S. tax ruling benefit and litigation settlement income, while non-GAAP EPS fell to $7.51 from $7.70. Operating cash flow was $13.9 billion, and net debt declined to $27.1 billion. The more important forward-looking issues are the patent cliff and acquisitions. Revlimid guidance calls for a $1.5 to $2.0 billion decline in 2024. Eliquis faces IRA government price-setting beginning in 2026 and ongoing European generic challenges, and Opdivo's exclusivity is estimated to run only to 2028 in the U.S. Management is also executing large acquisitions: Mirati closed in January 2024, while Karuna ($14.0 billion) and RayzeBio ($4.1 billion) are expected to close in the first half of 2024 and will be largely debt-funded. S&P downgraded the long-term rating to A from A+, and Moody's placed a negative outlook on its A2 rating. For investors, the core question is whether the pipeline, the new launches (Reblozyl, Breyanzi, Camzyos, Sotyktu, Augtyro), and the Mirati, Karuna, and RayzeBio assets can offset the roughly $8.7 billion of 2024 intangible amortization and the loss of exclusivity on major products. The filing presents a credible growth portfolio but a leverage-constrained balance sheet and meaningful near-term revenue erosion risk.

Feb 13, 2024 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Feb 2, 2024)

Bristol Myers Squibb's Q4 and full-year 2023 results, reported February 2, 2024, showed a mixed picture: top-line stability with strong growth from the new product portfolio offset by steep erosion of Revlimid. Q4 revenues were $11.5 billion, up 1% reported and flat ex-FX, with the in-line and new product portfolio up 9% to $9.8 billion. Full-year revenues fell 2% to $45.0 billion, but the in-line and new product portfolio grew 7% to $37.9 billion, while recent loss-of-exclusivity products (Revlimid and Abraxane) declined 34% to $7.1 billion. GAAP EPS was $0.87 in Q4 and $3.86 for the year; non-GAAP EPS was $1.70 in Q4 and $7.51 for the year, down 2% from $7.70 in 2022. The company's strategic focus centered on portfolio diversification through business development. BMS completed the acquisition of Mirati Therapeutics in January 2024 and agreed to acquire Karuna Therapeutics and RayzeBio, both expected to close in the first half of 2024, along with a licensing collaboration with SystImmune. Management guided 2024 non-GAAP EPS to $7.10 to $7.40 and total revenues to a low single-digit increase, excluding the pending transactions. Management also disclosed roughly $800 million in upfront Acquired IPRD charges in Q1 2024 and expected dilution of about $0.30 from financing and $0.13 from operations, which investors will need to weigh against the guidance. For investors, the key questions are whether the growth portfolio (Opdivo, Reblozyl, Breyanzi, Camzyos, Zeposia, Sotyktu) can offset the Revlimid cliff and the upcoming Eliquis and other patent expirations, and whether the pending acquisitions create long-term value. The company also announced a $0.60 quarterly dividend, a 5.3% increase, and an additional $3 billion share repurchase authorization, bringing total authorization to about $5 billion. Net debt was $27.1 billion at year-end 2023, down from $30.1 billion a year earlier.

Feb 2, 2024 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Regulation FD Disclosure (Jan 8, 2024)

Bristol Myers Squibb furnished an investor presentation on January 8, 2024, timed to the J.P. Morgan Healthcare Conference, under Item 7.01 (Regulation FD). The filing itself contains no new financial results; its substance is management's strategic framing. BMS describes a 'transition period' through 2025, during which it aims to maximize performance from its Legacy Portfolio (about $25B of 2023 sales) while facing loss of exclusivity on several major products, Inflation Reduction Act (IRA) pricing pressure, and intensifying competition. The company says sustainable, top-tier growth is expected from the late 2020s, driven by its Growth Portfolio and a pipeline of 12 registrational-stage and 30+ early-stage assets. Management reaffirmed its previously issued financial targets: a low-to-mid single-digit revenue CAGR from 2020-2025 at constant exchange rates, a low double-digit CAGR excluding Revlimid and Pomalyst, $8B-$10B of growth from in-line brands, more than $10B of revenue from the new product portfolio in 2026, an operating margin above 37% through 2025 (excluding future business development), and $25B of non-risk-adjusted sales from the New Product Portfolio by 2030. Business development is positioned as a continued priority, with recent and pending deals including Mirati, Karuna, RayzeBio and SystImmune, all expected to close in the first half of 2024. These acquisitions are central to the growth thesis but add integration and execution risk. For investors, the key takeaways are the company's dependence on successful execution of its late-stage pipeline (including Breyanzi, Camzyos, Sotyktu, milvexian, KarXT and CD19 NEX T) to offset legacy erosion, and the reliance on pending acquisitions closing on schedule. The presentation contains forward-looking statements and non-GAAP measures and does not provide updated quantitative guidance beyond the reaffirmed targets.

Jan 8, 2024 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Dec 22, 2023)

On December 22, 2023, Bristol-Myers Squibb (BMY) and Karuna Therapeutics (KRTX) announced a definitive merger agreement under which BMS will acquire Karuna for $330.00 per share in cash, representing a total equity value of approximately $14.0 billion, or $12.7 billion net of estimated cash acquired. The price represents a premium of roughly 53.4% to Karuna's December 21, 2023 closing price. The transaction was unanimously approved by both boards and is expected to close in the first half of 2024, subject to Karuna stockholder approval and required regulatory clearances. The strategic rationale centers on Karuna's lead asset, KarXT (xanomeline-trospium), a potential first-in-class M1/M4 muscarinic agonist for schizophrenia, with an FDA PDUFA date of September 26, 2024. BMS management expects KarXT to drive growth through the late 2020s and into the next decade, with additional opportunities in adjunctive schizophrenia (data expected 2025), Alzheimer's disease psychosis (data expected 2026), and potentially bipolar I disorder and Alzheimer's agitation. BMS also cited differentiated safety, with no meaningful weight gain, extrapyramidal symptoms, prolactin elevation, akathisia, or sedation reported. For BMY shareholders, the key financial considerations are dilution and financing. BMS expects the deal to reduce non-GAAP diluted EPS by approximately $0.30 in 2024, driven by financing costs, which it expects to offset through cost efficiencies and portfolio prioritization. The acquisition will be funded primarily with new debt, and management reiterated its commitment to strong investment-grade credit ratings, business development, dividends and share repurchases. The filing notes uncertainty around the accounting treatment (business combination versus asset acquisition), to be determined at closing.

Dec 22, 2023 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Nov 13, 2023)

Bristol-Myers Squibb Company (BMY) has filed an 8-K report detailing the successful completion of a substantial public offering of notes totaling $4.5 billion. The offering comprises four tranches with varying interest rates and maturity dates, ranging from 2031 to 2063. The company intends to utilize the net proceeds from this offering for general corporate purposes, with a specific mention of financing the proposed acquisition of Mirati Therapeutics, Inc., and associated fees and expenses. This issuance represents a strategic move to secure funding for significant future investments and operational needs. The notes are governed by an indenture, which includes customary covenants and restrictions related to incurring secured debt, engaging in sale/leaseback transactions, and significant corporate actions like mergers. The company retains the option to redeem the notes prior to maturity, with redemption terms outlined for both 'make-whole' provisions before a certain date and at par value on or after the applicable 'Par Call Date.' Investors should note the specific interest rates and maturity dates, as well as the company's flexibility in early redemption.

Nov 13, 2023 8-K

BRISTOL MYERS SQUIBB CO 8-K/A Report, Executive Changes (Oct 31, 2023)

This 8-K/A filing from Bristol Myers Squibb (BMY) provides an update on leadership transitions and associated compensation, primarily concerning the CEO role. Effective November 1, 2023, Dr. Christopher Boerner will assume the CEO position, taking over from Dr. Giovanni Caforio, who will transition to Executive Chairman. This amendment clarifies that Dr. Caforio will not stand for re-election to the Board and will retire on April 1, 2024, at which point Dr. Boerner will also assume the role of Chairman of the Board. The filing details Dr. Boerner's new compensation package as CEO, including a base salary of $1,500,000, a target bonus of 150% of base salary, and additional long-term incentive awards valued at $1,600,000. Dr. Caforio's compensation remains unchanged during his transition to Executive Chairman, but he will not receive further long-term incentive awards. Investors should note the structured handover and the confirmation of Dr. Boerner's leadership into the Chairman role.

Oct 31, 2023 10-Q

BRISTOL MYERS SQUIBB CO Quarterly Report for Q3 Ended Sep 30, 2023

Bristol-Myers Squibb's Q3 2023 10-Q shows a quarter with declining top-line revenue but a sharp rise in GAAP earnings. Total revenues fell 2% to $10.97 billion for the quarter and 4% to $33.53 billion year-to-date, driven mainly by Revlimid's generic erosion (down 41% in Q3) and Revlimid patient-assistance free-drug shifts. Offsetting growth came from Opdivo (up 11% in Q3), Eliquis (up 2%), Reblozyl, Breyanzi, Opdualag, Zeposia and Camzyos. GAAP diluted EPS rose to $0.93 in Q3 from $0.75, and to $2.99 year-to-date from $2.00, but this was largely driven by specified items such as lower equity investment losses, lower amortization, litigation settlement income (including the AstraZeneca settlement), Nimbus change-of-control income, and a $656 million non-U.S. tax ruling benefit. Management reported non-GAAP EPS of $2.00 for Q3 (vs. $1.99) and $5.80 year-to-date (vs. $5.88), so underlying earnings were roughly flat to slightly down. Balance sheet and cash flow remain sizable but are shifting. Operating cash flow was $9.6 billion year-to-date, funding $3.6 billion of dividends and $5.2 billion of buybacks, including a $4.0 billion accelerated share repurchase in Q3. Total debt fell to about $37.0 billion, and the net debt position was $29.6 billion. Total assets declined to $91.3 billion, mainly because intangible assets fell to $29.0 billion from $35.9 billion through amortization. Management also announced the pending $4.8 billion all-cash acquisition of Mirati Therapeutics (plus a CVR of up to about $1.0 billion), expected to close by the first half of 2024, along with a $1.0 billion restructuring plan through 2025. The filing highlights several forward risks: Revlimid's continuing erosion, pending European and U.S. Eliquis and other patent litigation, the Inflation Reduction Act's drug price negotiation (Eliquis was selected in August 2023, and BMS has sued the government), a $1.0 billion-plus restructuring program, and an effective tax rate that fell to 7.2% for the nine months because of one-time items. Investors will need to see whether Opdivo, the New Product Portfolio and the Mirati pipeline can offset Revlimid and Eliquis pressure.

Oct 26, 2023 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Oct 26, 2023)

Bristol Myers Squibb reported third-quarter 2023 total revenues of $11.0 billion, down 2% year over year (3% excluding foreign exchange), as steep declines in Revlimid (down 41%, generic erosion and increased free drug to the patient assistance foundation) offset growth in its in-line and new product portfolios. The in-line and new product portfolio grew 8% (7% ex-FX) to about $9.3 billion, led by the new product portfolio, which rose 68% to $928 million. GAAP EPS was $0.93, up 24% year over year, while non-GAAP EPS was $2.00, up 1%. GAAP margin compression reflected product mix and lower hedge gains, and the GAAP tax rate fell to 9.5% on a non-U.S. R&D deductibility ruling. Management raised the midpoint of 2023 non-GAAP EPS guidance to $7.50-$7.65 (from $7.35-$7.65 range midpoint of $7.50 vs. prior $7.50 low end, with the range narrowed) and cut GAAP EPS guidance to $3.68-$3.83 from $3.72-$4.02, while raising Revlimid 2023 revenue expectations to about $6.0 billion from $5.5 billion. The company will stop providing GAAP guidance starting with Q4 and full-year 2023 results. It also lowered its 2025 operating margin target to above 37% from 40%+ and pushed the >$10 billion new product portfolio revenue goal out to 2026 from 2025. The most consequential strategic item is the planned acquisition of Mirati Therapeutics, which adds the approved KRAS G12C inhibitor KRAZATI (adagrasib) and an early PRMT5 inhibitor, with closing expected by the first half of 2024. Investors should weigh the Revlimid generic erosion, the Eliquis international pressures, the Mirati integration and deal execution, and the pending pipeline readouts, including the repotrectinib FDA decision date of November 27, 2023, against the continued growth in Opdivo, Reblozyl, Zeposia and the broader new product portfolio.

Oct 26, 2023 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Corporate Update (Aug 10, 2023)

Bristol-Myers Squibb Company (BMY) announced on August 9, 2023, that it has entered into accelerated share repurchase (ASR) agreements to buy back an aggregate of $4.0 billion of its common stock. These transactions are part of a previously authorized multi-year share repurchase program and are being executed with major financial institutions including Bank of America, Citibank, JPMorgan Chase, and Morgan Stanley. The ASR transactions are designed to return capital to shareholders and reflect the company's confidence in its financial position and future prospects. While an initial portion of the shares will be delivered promptly, the final number of shares repurchased will be determined by volume-weighted average prices over the repurchase period, with potential adjustments. This move is a significant capital allocation decision that investors will want to monitor for its impact on earnings per share and overall shareholder value.

Aug 10, 2023 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Jul 27, 2023)

Bristol Myers Squibb reported Q2 2023 total revenues of $11.2 billion, down 6% year over year (5% excluding foreign exchange), driven primarily by a steep decline in Revlimid sales following generic erosion and a rise in free-drug distribution through the Bristol Myers Squibb Patient Assistance Foundation. GAAP EPS was $0.99 (up 50%, helped by a non-U.S. tax ruling benefit and lower equity investment losses), while non-GAAP EPS fell 9% to $1.75. The company's in-line products grew 3% in the U.S. but the global in-line portfolio was down 5% ex-FX due to Eliquis and Revlimid international generic erosion. The new product portfolio was the clear bright spot, reaching $862 million in quarterly sales, up 79%, and management says it is approaching a roughly $3.5 billion annual run rate. The most important news for investors is the guidance cut. Management lowered its 2023 Revlimid expectation from about $6.5 billion to about $5.5 billion and now expects total revenues to decline by a low single digit percentage, versus prior guidance of roughly 2% growth. GAAP EPS guidance was revised to $3.72-$4.02 from $4.10-$4.40, and non-GAAP EPS guidance to $7.35-$7.65 from $7.95-$8.25. Management also said Revlimid revenue is expected to step down by roughly $1.5 billion in 2024 and $2 billion in 2025, which raises questions about the trajectory of the 2020-2025 targets. Management reaffirmed those targets, including low- to mid-single-digit revenue CAGR at constant exchange rates and at least a 40% non-GAAP operating margin. Capital allocation remains a focus. The company announced a $4 billion accelerated share repurchase to be executed in Q3 2023, and it continues debt reduction, with about $1.9 billion of year-to-date repayments and roughly $2 billion of additional 2023 maturities. Total cash was about $8.7 billion against total debt of about $37.7 billion at quarter-end. Pipeline milestones included FDA acceptance of repotrectinib with a PDUFA date of November 27, 2023, a Reblozyl first-line MDS PDUFA date of August 28, 2023, and the failure of the CheckMate-7DX Phase 3 trial in prostate cancer.

Jul 27, 2023 10-Q

BRISTOL MYERS SQUIBB CO Quarterly Report for Q2 Ended Jun 30, 2023

Bristol-Myers Squibb's Q2 2023 results (quarter ended June 30, 2023) show total revenue down 6% year-over-year to $11.2 billion, driven by steep Revlimid erosion (down 41% in the quarter to $1.47 billion) as generic lenalidomide enters the U.S. and Europe. Net product sales fell 5%, with International revenues down 8% and U.S. down 5%. Growth came from In-Line Products (Eliquis, Opdivo, Yervoy) and the New Product Portfolio, which rose 79% to $862 million, led by Reblozyl, Abecma, Opdualag, and Breyanzi. GAAP diluted EPS rose to $0.99 from $0.66, but this was flattered by a $656 million deferred tax benefit from a non-U.S. tax ruling and by lower equity investment losses. Non-GAAP diluted EPS fell to $1.75 from $1.93, reflecting lower revenue. Profitability and cash generation remain solid but are under pressure. Six-month operating cash flow was $4.9 billion, down $1.2 billion from 2022, and the net debt position improved by $1.1 billion to $28.9 billion. BMS returned capital through $2.4 billion of dividends and $1.2 billion of buybacks in the first half, with a $4.0 billion accelerated share repurchase announced for Q3 2023. Management flagged that the Inflation Reduction Act could have a material impact on the business, and it filed a lawsuit challenging the law's constitutionality on June 16, 2023. The most important medium-term issues are the continued Revlimid decline (guided to about $5.5 billion globally in 2023), the Eliquis generic challenges in Europe and the U.S., and whether the New Product Portfolio can offset the loss of exclusivity. Legal developments were mixed. BMS settled with AstraZeneca for an aggregate $560 million (BMS share about $418 million, recognized in Q3 2023), and it won an Australian Plavix damages appeal, while a Hawaii Plavix penalty was remanded for a new trial.

Jul 27, 2023 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (May 4, 2023)

Bristol Myers Squibb Company (BMY) announced significant leadership changes and reported the outcomes of its Annual Meeting of Shareholders held on May 2, 2023. The most notable development is the appointment of Dr. Christopher Boerner as Chief Operating Officer effective April 26, 2023, and his subsequent appointment as Chief Executive Officer effective November 1, 2023. Dr. Boerner has also been elected to the Board of Directors, increasing its size to twelve members. While he is a key executive, the Board has determined he is not independent under NYSE standards and will not serve on any Board committees, nor will he receive compensation for his director role. The Annual Meeting also saw shareholders re-elect all eleven incumbent directors, approve the compensation of named executive officers on an advisory basis, and vote for an annual advisory vote on executive compensation. Additionally, Deloitte & Touche LLP was ratified as the independent registered public accounting firm for 2023. However, shareholder proposals regarding an independent Board Chairperson and improvements to special shareholder meetings did not pass.

May 4, 2023 8-K

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Apr 27, 2023)

Bristol Myers Squibb reported first-quarter 2023 total revenues of $11.3 billion, down 3% year over year (down 1% excluding foreign exchange), largely reflecting Revlimid generic erosion and currency headwinds. The more encouraging story is the growth engine: in-line products and the new product portfolio together rose 8% to $9.3 billion (10% ex-FX), led by Eliquis, Opdivo, Opdualag, Abecma, and Reblozyl. U.S. revenues grew 4% to $8.0 billion, while international revenues fell 16% to $3.3 billion, mainly from generic erosion of Revlimid and Eliquis in Canada and the U.K. Profitability showed a mixed picture. GAAP diluted EPS rose to $1.07 from $0.59, largely from lower equity investment losses and higher litigation and other settlement income, while non-GAAP EPS rose 5% to $2.05. Gross margin compressed modestly on a non-GAAP basis (77.8% vs. 79.2%) due to product mix. Management affirmed 2023 non-GAAP EPS guidance of $7.95 to $8.25 and revenue growth of about 2%, but revised GAAP EPS guidance upward to $4.10 to $4.40 from $4.03 to $4.33, driven by settlement income and equity investment fair value changes. For investors, the key questions are whether the in-line and new product growth can offset the roughly $6.5 billion Revlimid decline, the pace of pipeline milestones (including several FDA and EMA decisions later in 2023), and the company's continued debt reduction, with net debt falling to about $28.6 billion at quarter end from $30.1 billion at year end.

Apr 27, 2023 10-Q

BRISTOL MYERS SQUIBB CO Quarterly Report for Q1 Ended Mar 31, 2023

Bristol-Myers Squibb's first quarter 2023 results showed total revenues of $11.3 billion, down 3% from $11.6 billion a year earlier, as Revlimid generic erosion (revenue down 37% to $1.75 billion) and a roughly 2% foreign exchange headwind outweighed growth in Opdivo, Eliquis, and the New Product Portfolio. GAAP diluted EPS rose to $1.07 from $0.59, but much of the improvement reflects specified items such as lower equity investment losses and a $400 million Nimbus/Takeda TYK2 change-of-control payment recorded in litigation and other settlements. On a non-GAAP basis, diluted EPS increased to $2.05 from $1.96, helped by lower acquired IPRD charges, a smaller share count, and higher royalty and interest income. Cash generation was solid, with $3.0 billion of operating cash flow, though it fell from $3.8 billion a year earlier on working capital timing. The company spent $1.2 billion on dividends and $250 million on buybacks, repaid $1.6 billion of maturing debt, and reduced net debt by $1.5 billion to $28.6 billion. Remaining buyback authorization stood at about $6.9 billion. The balance sheet shows total assets of $94.3 billion, with intangible assets declining to $33.6 billion as amortization continues. The key risks for investors are the ongoing loss of exclusivity for Revlimid and the pending generic entry for Eliquis in Europe and, potentially, in the U.S. Management also flagged IRA-related pricing pressure and a pending IRS dispute over 2008-2012 transfer pricing. Growth from newer launches such as Abecma, Opdualag, and Reblozyl is helping to offset these headwinds, but it has not yet fully replaced the lost revenue.

Apr 27, 2023